Clinical Trial Detail

NCT ID NCT02740985
Title A Phase 1 Clinical Study of AZD4635 and Durvalumab in Patients With Advanced Solid Malignancies
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors AstraZeneca
Indications

Advanced Solid Tumor

lung non-small cell carcinoma

Therapies

AZD4635

AZD4635 + Durvalumab

Age Groups: adult senior

No variant requirements are available.